Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
This trial is active, not recruiting.
|Condition||advanced hormone dependent prostate cancer|
|Start date||March 2013|
|End date||August 2018|
|Trial size||103 participants|
|Trial identifier||NCT01861236, 000036|
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
Progression-free survival (PFS) failure rate (with failure defined as either prostate-specific antigen (PSA) failure, introduction of additional therapy related to prostate cancer, or death)
time frame: During 3 years treatment
Male participants from 18 years up to 100 years old.
Inclusion Criteria: - Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice - Written informed consent Exclusion Criteria: - Contraindications to Firmagon - Patients already on Firmagon therapy
|Official title||Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina|
Call for more information